PharmaEngine, Inc. 4162.TWO
1H 2026 Investors' Conference
2026/08/06

Roger Hsieh, Associate Director, Business Development
Jackie Chang, Senior Manager, Investor Relations

Disclaimer

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future,’ or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. Pricing and product initiatives of competitors
2. Legislative and regulatory developments and economic conditions
3. Delay or inability in obtaining regulatory approvals or bringing products to market
4. Fluctuations in currency exchange rates and general financial market conditions
5. Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products
6. Increased government pricing pressures
7. Interruptions in production
8. Loss of or inability to obtain adequate protection for intellectual property rights
9. Litigation
10. Loss of key executives or other employees
11. Adverse publicity and news coverage

PharmaEngine cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. PharmaEngine undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that PharmaEngine ’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of PharmaEngine, Inc.

AGENDA

1. 1H 2026 Operational Highlights
2. 1H 2026 Operational Overview
3. R&D Pipeline and Related Markets Update
   - PEP07 (CHK1 Inhibitor)
   - PEP08 (2nd Generation PRMT5 Inhibitor)
4. Company Outlook
5. Q&A

1H 2026 Operational Highlights: Sustainable Growth and Enhanced Pipeline

COMMERCIAL

ONIVYDE® Indication Expansion

1. Sales of 1L combination therapy of ONIVYDE® in various EU countries have been boosting revenue growth
2. Continue to advance ONIVYDE's 1L PDAC marketing and sales strategies in Taiwan, providing patients with more treatment options

PIPELINE

Expand R&D Pipeline Acceleration

1. PEP07 Phase I clinical trials for hematologic/solid tumors plan to begin dose expansion and combo treatment trials before end of 2026
2. PEP08 Phase I dose escalation for solid tumors is ongoing
3. Other projects continue to move forward.

OPERATION

Operation with Sustainable Growth

1. 1H26 cash and cash equivalents and current financial assets (>3 months time deposits) at amortized cost: NT$5.07bn
2. 2025 cash dividend: NT$2/share, scheduled distribution date is September 4
3. From January to June 2026, green energy consists 30% of our energy mix

1H 2026
OPERATIONAL OVERIVEW

Sales and Royalties Drive Long-term Growth

NT$(000)

Item / Year	2019	2020	2021	2022	2023	2024	2025	1H 2026 YoY (%)
Taiwan Sales	180,389	214,828	235,469	277,594	278,547	279,990	277,133	131,457 (+3%)
Royalties from Europe and Asia	133,651	271,584	419,366	376,789	426,652	543,286	627,762	312,684 (+25%)
Milestone/Sub-license Revenue	0	569,600	0	0	62,470	1,700,028	6,521	53,670 (+723%)
Total	314,040	1,056,012	654,835	654,383	767,669	2,523,304	911,416	497,811 (30%)

1H 2026 Financial Results

NT$(000)	1H 2026	1H 2025	Amount Change	% Change
Operating revenue	497,811	384,169	113,646	30%
Operating costs	34,186	23,207	10,979	47%
Gross profit	463,625	360,962	102,663	28%
Sales expenses	16,615	15,091	1,524	10%
G&A expenses	48,395	45,781	2,614	6%
R&D expenses	152,271	113,362	38,909	34%
Total operating expenses	217,281	174,234	43,047	25%
Operating income	246,344	186,728	59,616	32%
Total non-operating income and expenses	62,333	(15,296)	77,629	508%
Income before income tax	308,677	171,432	137,245	80%
Income tax expense	37,427	51,344	(13,917)	(27%)
Profit for the period	271,250	120,088	151,162	126%
EPS (NT$)	1.89	0.84	1.05	125%

R&D Pipeline and Related Markets Update

Pipeline Portfolio Focuses on Precision Oncology

Program		Indications	Lead	Preclinical	Phase I	Phase II	Phase III	Approval	Commercial Rights	Partner
ONIVYDE® (liposomal irinotecan)		1L/2L PDAC	Approval						Milestone Royalty (EU/Asia) Taiwan Sales	IPSEN Innovation for patient care
DDR & Synthetic Lethality	PEP07 (CHK1i)	AML/MCL							Global	Sentinel ONCOLOGY
		Solid tumors								
	PEP08 (PRMT5i)	MTAP-del cancers							Global	PEI Owned
	PEP09	Undisclosed							Global	Undisclosed
	PEP10	Undisclosed							Global	PEI Owned

PEP07: CHK1 Inhibitor

Mechanism

PEP07 is a checkpoint kinase 1 (CHK1) inhibitor which targets the DNA Damage Response (DDR) pathway. CHK1 inhibitors have important functions in the cell's DDR process as it can enhance the damaging effect of cytotoxic therapy on DNA and prevent the self-repair of tumor cells leading to tumor cell deaths.

Characteristics

Potentially the best-in-class CHK1 inhibitor:

- ✓ **High selectivity**
- ✓ **Oral bioavailability**
- ✓ **BBB-penetrating**

PEP07 also has demonstrated significant monotherapy activity and combination potential with standard treatments in preclinical models.

Highly potential indications and number of patients (2022 GLOBOCAN data)

- ✓ **Acute Myeloid Leukemia (2022: 165,500 incidences)**
- ✓ **Mantle Cell Lymphoma (2022: 33,323 incidences)**
- ✓ **Glioblastoma (2022: 321,476 incidences)**

Global DDR Drugs Market Size Forecast



DDR drugs market size is forecasted to grow from US$9.4 billion in 2025 to US$33.1 billion in 2035, with a CAGR of 13.4%

Source: Precedence Research, 2026

PEP07: Phase I Clinical Trial Update

Target Population

Monotherapy for patients with advanced or metastatic hematologic cancers and solid tumor ; combo studies for the selected cancer types.

Dose Escalation Endpoint

- Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
- Pharmacokinetics (PK), Pharmacodynamics (PD), preliminary therapeutic effect, and biomarkers

Status Update

Dose escalation is near completion in Australia and Taiwan.



- Safety
- Dosage Exploration
- Pharmacokinetics (PK)
- Pharmacodynamics (PD)

Target: Enroll the first patient for combination studies before end of 2026

PEP08: Second-Generation PRMT5 Inhibitor

Mechanism

PEP08 is a second-generation MTA-cooperative, PRMT5 inhibitor and a highly selective small molecule designed to specifically target MTAP-deleted cancer and less affect the growth of normal cells. It is expected to have a better therapeutic window and safety profile.

Characteristics

Potentially the best-in-class PRMT5 inhibitor:

- ✓ **High selectivity**
- ✓ **Oral bioavailability**
- ✓ **BBB-penetrating**

Highly potential indications (MTAP-deletion) and number of patients (2022 GLOBOCAN data)

- ✓ **Glioblastoma (2022: 135,020 incidences)**
- ✓ **Lung Cancer (2022: 274,040 incidences)**
- ✓ **Pancreatic Cancer (2022: 112,325 incidences)**

Global Synthetic Lethality Drugs Market Size Forecast



The global synthetic lethality drugs market is forecasted to grow from US$4.2 billion in 2024 to US$17.6 billion in 2033, with a CAGR of 17.3%

Source: HKEX Publication, 2026

PEP08: Phase I Clinical Trial Update

Target Population

Patients with advanced or metastatic MTAP-deficient solid tumors

Dose Escalation Endpoint

- Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
- Pharmacokinetics (PK), Pharmacodynamics (PD), preliminary therapeutic effect, and biomarkers

Status Update

Dose escalation in Australia, Taiwan, and South Korea continues to progress.



Plan to conduct backfill cohorts (increase the number of cases) in the selected effective dose group

Target: Complete patient enrollment in dose escalation in the end of 2026

Combination Therapy: A Major Trend in Modern Cancer Treatment

Combination Therapy

Combination therapy has emerged as a key approach in cancer treatment. By integrating therapies with different mechanisms of action, it can enhance treatment efficacy, extend disease control, and reduce the risk of drug resistance.

Enhance Competitiveness

PharmaEngine is exploring combination therapies with SoC, NCEs, and pipeline assets to broaden clinical indications, enhance commercial value, and strengthen its portfolio.



PEP07 + PEP08 Combo Therapy Shows Therapeutic Potential in CDX Model

Pancreatic Cancer CDX



GBM (brain cancer) CDX



PEP07 + PEP08 combination therapy shows synergistic effects in pancreatic cancer and GBM (brain cancer) in CDX models

Company Outlook

Business Development Momentum

Clinical Trial Collaboration

- Actively explore the potential preclinical and clinical partners for PEP07 and PEP08
  - Target on selected indications
  - On-market drugs or under-developed drugs
  - International and domestic academic research institutions, medical centers, or MNC pharmaceutical companies

Out-Licensing

- For major global markets, we are evaluating licensing collaborations and joint development models to accelerate product development, clinical validation, and future commercialization. Related collaboration opportunities are gradually gaining momentum.
- Regional development and commercialization rights (Asia, Europe, and America)
- Global development and commercialization rights (exclude Taiwan)

Innovative Drug Development & AI Platform Strategic Collaboration

CADD to Generative AI

Before 2020: The biotech industry began using computer-assisted drug development (CADD), mainly to use computer to screen candidate compounds.

With the rise of generative AI, novel compounds with target properties can now be designed directly.

Generative AI Platform

2020-Now: AI accelerates early drug discovery by enabling target identification, molecule generation, and property prediction.

Innovative Drug Development Strategy

PharmaEngine aims to drive innovative drug discovery and to strengthen in-house R&D capabilities. Since **2022**, we partnered with leading AI drug discovery companies. Combining our extensive R&D experiences with AI platform for PEP08, **drug discovery** to **Phase I ready** only took 2.5 years compared to the conventional 5–8 years. **PharmaEngine will continue to accelerate development and improve R&D efficiency to provide more therapy options for cancer patients.**



Company Outlook (2H26 Onward)

1. Begin the combination study for PEP07
2. Complete dose escalation for PEP08
3. Accelerate the R&D pipeline combination
4. Actively looking for out-licensing and clinical collaboration partners
5. Collaborate with AI Drug Discovery partner to expand PEI portfolio
6. 30% of green energy in operation-use electricity mix in 2026, increase 10% every year

THANK YOU

PharmaEngine, Inc.